QUINTESSENTIAL

A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)

What's the purpose of the trial?

The purpose of this study is to evaluate the effectiveness and safety of BMS-986393 in participants with relapsed or refractory multiple myeloma.
Trial status

Accepting patients

Phase
Phase 2
Enrollment
150
Last Updated
2 weeks ago
Am I Eligible

Participating Centers

There are 36 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • BMS-986393 (CC-95266) is an investigational CAR T-cell product that is being studied for use in multiple myeloma. Researchers think that BMS-986393 can work by reprogramming T-cells in the immune system to target and destroy cancer cells.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

BMS-986393

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.